Effect of Magnesium Supplementation on Elevated Systolic Blood Pressure

Description

The purpose of this study is to assess whether 480 mg/day magnesium glycinate supplementation for 12 weeks lowers blood pressure.

Conditions

Blood Pressure

Study Overview

Study Details

Study overview

The purpose of this study is to assess whether 480 mg/day magnesium glycinate supplementation for 12 weeks lowers blood pressure.

Trial of Magnesium Supplementation and Blood Pressure Reduction Among Adults with Elevated Systolic Blood Pressure

Effect of Magnesium Supplementation on Elevated Systolic Blood Pressure

Condition
Blood Pressure
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Self-report of systolic blood pressure 125-159 mmHg
  • * Measured seated systolic blood pressure 130-159 mmHg at screening visit
  • * Body mass index less than 40 kg/m2
  • * Total magnesium intake from supplements of no more than 100 mg/day
  • * Willing to maintain current diet and supplement use patterns during the 12-week intervention period
  • * Measured seated diastolic blood pressure 100 mmHg or greater at screening visit
  • * Antacid or laxative use 4 times/week or more within the past 3 months
  • * History of cardiovascular disease (myocardial infarction, stroke, revascularization \[coronary artery bypass graft or percutaneous transluminal coronary angioplasty\], or angina pectoris)
  • * History of invasive cancer diagnosed within the last 5 years (non-melanoma skin cancer permitted)
  • * History of type 1 or 2 diabetes
  • * History of renal disease
  • * History of kidney failure
  • * History of dialysis
  • * History of pancreatitis
  • * History of inflammatory bowel disease
  • * History of hypermagnesemia
  • * Women who are pregnant, nursing, or intend to become pregnant during the period of treatment
  • * Plan to relocate out of Boston area within the next year
  • * Unwillingness and/or inability to swallow 4 pills per day
  • * Inability to provide written informed consent

Ages Eligible for Study

30 Years to 74 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Brigham and Women's Hospital,

Study Record Dates

2025-08